[go: up one dir, main page]

EP0365571A1 - Un medicament pour traiter l'oeil et support approprie - Google Patents

Un medicament pour traiter l'oeil et support approprie

Info

Publication number
EP0365571A1
EP0365571A1 EP88905769A EP88905769A EP0365571A1 EP 0365571 A1 EP0365571 A1 EP 0365571A1 EP 88905769 A EP88905769 A EP 88905769A EP 88905769 A EP88905769 A EP 88905769A EP 0365571 A1 EP0365571 A1 EP 0365571A1
Authority
EP
European Patent Office
Prior art keywords
eye
patient
gel formation
drops
components
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP88905769A
Other languages
German (de)
English (en)
Inventor
Christian Bannert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP0365571A1 publication Critical patent/EP0365571A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Definitions

  • the invention relates to the use of a medicament comprising at least two components capable of gel formation with one another.
  • gels To treat diseases of the mucous membranes, it has proven useful to use gels. On the one hand, they can be used to protect and keep mucous membranes moist. On the other hand, they are used to apply disinfectants and drugs to the mucous membrane and let them work there. These gels, which are made from synthetic or vegetable substances and can contain various active ingredients, are applied to the mucous membrane in the nose, mouth, throat or urogenital area.
  • Another problem is the application of drugs to the cornea and conjunctiva of the eye.
  • Conjunctiva of the eye Conjunctiva of the eye.
  • the residence time of these gels on the cornea and conjunctiva should last as long as possible, on the one hand to keep the eye moist and on the other hand to allow the active ingredients to act locally.
  • a problem with the previously known agents for treating the eye is that they do not adhere sufficiently and are flushed out through the tear duct by the tear fluid. Therefore, the application must be carried out at shorter intervals and in higher doses than would be necessary with good adhesion, which is very uncomfortable for the patient.
  • diseases such as glaucoma, where constant treatment with drugs is required, it would be desirable to find a form of application that enables less frequent use and lower doses.
  • the object of the invention was therefore to prevent the known disadvantages and to create a method for improving the adhesion of gels to the mucous membrane of the eyes.
  • This goal is achieved by using a medicament consisting of at least two components capable of gel formation which are applied simultaneously or successively for the treatment of the eye. It has surprisingly been found that if not the finished gel, but components capable of gelation, are applied to the mucous membrane, which then form a gel on the mucous membrane, good adhesion can be achieved. Adhesive gels form for a long time, which do not impair vision.
  • the viscose layer formed in accordance with the invention is similar to the mucin film usually found on the eye.
  • the oligosaccharide side chains of the mucin like the polyuronic acids of the alginates, carry a negative charge.
  • the gel films produced according to the invention therefore adhere very persistently to the surface of the cornea and also stabilize the tear film, which thereby adheres better and wets the surface of the cornea better.
  • the two components capable of gel formation are dissolved separately from one another.
  • the solutions are then applied sequentially or simultaneously.
  • the application can take place in the usual way.
  • the two components are preferably dripped into the lower eyelid crease.
  • Substances which lead to gel formation when mixed can be used as components capable of gel formation. They must also be compatible with the mucous membrane and must not be toxic. Combinations of alginic acid, polyguluronic acid, polymannuronic acid, propylene glycol alginic acid, polygalacturonic acid, their salts or esters or mixtures thereof are suitable, for example.
  • Calcium salts are preferably used as gel-forming components together with alginic acid or one of its derivatives or with a pectin with a low degree of esterification. Calcium salts react with alginic acid and pectins and their derivatives and form cross-linkages. With increasing content of the metal salt, thickening and then gel formation occur first.
  • Calcium salts are preferably used as the metal salt, it being possible to use all pharmaceutically acceptable salts as calcium salts, such as calcium chloride or calcium salts with organic anions such as citrate, lactate, aspartate, saccharate, oxovalerate, gluconate, lactobionate and lactogluconate. Calcium gluconate is preferably used.
  • the preferred alginic acid derivative is sodium alginate, of which all viscosity types can be used. They are classified by the viscosity of the 1% solution. The measurement is carried out at 25 ° C using a Brookfield viscometer. Commercial alginate types are:
  • the brown algae In addition to alginic acid, the brown algae also contain other mono- and polysaccharides. Fucose and ester sulfates are important for the mucous membranes. Suitable methods for processing the brown algae can be used to obtain mixtures of alginates, fucose and ester sulfates. These mixtures are also suitable as components for gel formation in the process according to the invention. - r -
  • the two components are used as a solution.
  • the metal salt is preferably used in a concentration of 0.01 to 2.5 mmol metal / 100 ml and the polysaccharide in a concentration of 0.01 to 1.0% by weight.
  • the concentration to be used can easily be determined. It also depends on the degree of viscosity of the polysaccharide used.
  • compositions which dissolve the respective component well are used as solvents.
  • Distilled water is preferably used, which is provided with a pharmaceutically acceptable preservative.
  • the gel formed according to the invention can be used as a tear replacement liquid to keep the eye mucosa moist or to protect it.
  • a disinfectant and / or pharmaceutical can additionally be applied to the eye mucosa with one of the components used according to the invention.
  • the gels obtained with the method according to the invention are preferably used as a carrier material for a medicament.
  • the drug in the dose to be administered is then introduced into one of the two component solutions and the solutions of the two components are then applied to the mucous membrane.
  • the two solutions are preferably applied in succession to the conjunctiva.
  • Another object of the invention is a carrier material for ophthalmic medicinal products which is characterized in that it contains at least two components capable of gel formation which are physically separate from one another. - b -
  • gels can be formed in a simple manner on the mucous membrane and adhere long and permanently to the cornea and conjunctiva.
  • At least one metal salt and at least one polysaccharide are preferably used as components of the agent according to the invention which are physically separate from one another.
  • a calcium salt is preferably used as the metal salt, and calcium chloride or an organic calcium salt is particularly preferably used.
  • Alginic acid, polyguluronic acid, polymannuronic acid, propylene glycol alginic acid, polygalacturonic acid, their salts or esters and mixtures thereof are particularly preferably used as the polysaccharide.
  • the two components are preferably dissolved in water.
  • One solution preferably contains 0.01 to 2.5 mmol metal / 100 ml, while the other solution preferably contains 0.01 to 1.0% by weight of at least one polysaccharide.
  • At least one of the two components of the composition according to the invention additionally contains medicinal substances, buffer substances, disinfectants, humectants and / or preservatives or other customary additives.
  • medicinal substances for example, sorbitol or glycerol is added to the agent to increase the flexibility of the gel. It may also be suitable to add surfactants to improve wetting.
  • the concentration of the two components of the agent according to the invention is generally approximately the same in each case. In special cases, however, it can be advantageous. -? -
  • the type of gel formed can also be influenced by the concentration.
  • the particularly adhesive gels obtained with the method according to the invention are particularly suitable for use as a tear replacement fluid and as a carrier material for medicaments or disinfectants.
  • drugs and disinfectants can be applied locally in a targeted manner.
  • Solution 2 sodium alginate (very high viscosity) 0.1% thiomersal 0.01%
  • Solution 1 sodium alginate (very highly viscous) 0.1% isotonic borate buffer, pH 7.6, 50 ml sodium chloride 0.45% thiomersal 0.01% distilled water ad 100.
  • Solution 2 Calcium gluconate * H_0 0.1% sodium chloride 0.7% benzalkonium chloride 0.01% pilocarpine hydrochloride 1% distilled water ad 100.
  • the dropping was carried out three times a day. After application of the drops, there was less irritation and a considerably lower disturbing effect due to the eyelashes on the eye. Therefore, the intervals at which the eyelashes had to be removed due to the disturbance reaction could be increased from approximately one week to two weeks. These results could not be achieved with the artificial tear fluid previously used.
  • a patient with chronic glaucoma was treated with drops according to Example 2. The drops were applied every 12 hours. Normalization of eye pressure has been observed with this therapy. With the pilocarpine eye drops previously used, which had to be applied four to five times a day, the eyes were severely irritated. Nevertheless, normalization of the eye pressure could not be achieved.
  • Example 1 treated.
  • the application frequency could be reduced.
  • the subjective condition improved and the burning and reddening of the eyes subsided.
  • the foreign body feeling in the eye also decreased.
  • Example 1 A patient who had been suffering from chronic recurrent conjunctivitis sicca with burning and reddening, especially in dry air, was treated with eye drops according to Example 1. The patient became symptom-free through two to three applications. Monthly checks confirmed this diagnosis.
  • the agent according to the invention three times a day, the condition could be significantly improved.
  • Example 1 treated. The eye drops are well tolerated when applied two or three times a day. Since then, the child has been much more free of complaints than before. Monthly checks confirmed this.
  • a patient with chronic fibrosing conjunctivitis after Lyell syndrome had expired was treated with eye drops prepared according to Example 1.
  • the drip frequency could be significantly reduced compared to other agents.
  • Example 1 eye drops produced a sudden improvement.
  • a patient with Sicca syndrome used eye drops according to Example 1 two to three times a day. The eye drops were well tolerated. Since then, the patient has been symptom-free.
  • a patient with chronic Staphylococcal Blepharo keratitis with Sicca syndrome had been treated with the eye drops obtained according to Example 1 for 8 months.
  • the eye drops were well tolerated.
  • the patient has been using the drops two to three times a day with unchanged good success for 8 months.
  • Isotonic borate buffer was produced according to the "Borax buffer according to Palitzsch" in OPTHALMICA, Volume 1, Pharmaceutical principles and their preparation,ticianliche Verlagsgesellschaft mbH Stuttgart, page 95, Table 3.2./7, (1975).
  • a patient with right-left angular block glaucoma was administered with eye drops obtained twice daily (8 a.m. / 8 p.m.) according to Example 15 in the right eye and 0.5% timolol (beta-blocker) in the same period in the left eye.
  • the measurement of the eye pressure gave the following values:
  • the eye drops according to the invention provide a better activity profile than known eye drops.
  • a patient with right-left angular block glaucoma with an identical pressure position on the right and left was applied twice in the right eye, at 8:00 a.m. and at 8:00 p.m., eye drops according to Example 15.
  • spersacarpine 0.5% and at 8.00 p.m. for the night Pilocarpol 2% was applied to his left eye for comparison three times, at 8:00 a.m., 12:00 p.m. and 6:00 p.m.
  • the values for the pressure measurement of both eyes can be found in the following table: - i -
  • the pressure curve is practically identical for both agents.
  • the pilocarpine dose can be reduced by a factor of 10 and at the same time the frequency of use can be reduced.
  • the eye drops of the prior art must be applied more frequently, which is uncomfortable for the patient.
  • the amount of pilocarpine must be 10 times higher to achieve the same result.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Un médicament comprenant deux constituants qui ensemble forment un gel pour traiter la muqueuse par application simultanée ou successive sur cette dernière est utilisé pour traiter l'oeil.
EP88905769A 1986-01-16 1988-06-23 Un medicament pour traiter l'oeil et support approprie Withdrawn EP0365571A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19863601132 DE3601132A1 (de) 1986-01-16 1986-01-16 Verfahren zur behandlung der schleimhaut
DE3721163 1987-06-26
DE19873721163 DE3721163A1 (de) 1986-01-16 1987-06-26 Traegermaterial fuer augenarzneimittel

Publications (1)

Publication Number Publication Date
EP0365571A1 true EP0365571A1 (fr) 1990-05-02

Family

ID=39361271

Family Applications (2)

Application Number Title Priority Date Filing Date
EP87900720A Expired - Lifetime EP0289512B1 (fr) 1986-01-16 1986-12-15 Procede d'amelioration de l'adhesivite de gels aux muqueuses
EP88905769A Withdrawn EP0365571A1 (fr) 1986-01-16 1988-06-23 Un medicament pour traiter l'oeil et support approprie

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP87900720A Expired - Lifetime EP0289512B1 (fr) 1986-01-16 1986-12-15 Procede d'amelioration de l'adhesivite de gels aux muqueuses

Country Status (5)

Country Link
US (1) US5147648A (fr)
EP (2) EP0289512B1 (fr)
JP (2) JPS63502186A (fr)
DE (2) DE3601132A1 (fr)
WO (2) WO1987004350A1 (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3601132A1 (de) * 1986-01-16 1987-07-23 Christian Bannert Verfahren zur behandlung der schleimhaut
US4988679A (en) * 1989-01-03 1991-01-29 Leonard Chavkin Liquid sustained release composition
US5089606A (en) * 1989-01-24 1992-02-18 Minnesota Mining And Manufacturing Company Water-insoluble polysaccharide hydrogel foam for medical applications
GB8911177D0 (en) * 1989-05-16 1989-07-05 Vilain Jean Alginate gel pharmaceutical product
FR2653021A1 (fr) * 1989-10-17 1991-04-19 Merck Sharp & Dohme Composition ophtalmique aqueuse liquide a transition de phase liquide-gel.
US5525351A (en) * 1989-11-07 1996-06-11 Dam; Anders Nicotine containing stimulant unit
SE9002339L (sv) * 1990-07-04 1992-01-05 Kabi Pharmacia Ab Terapeutisk komposition och foerfarande foer dess framstaellning
US5804213A (en) 1991-10-09 1998-09-08 Lectec Corporation Biologically active aqueous gel wound dressing
US5266326A (en) * 1992-06-30 1993-11-30 Pfizer Hospital Products Group, Inc. In situ modification of alginate
GB9218749D0 (en) * 1992-09-04 1992-10-21 Courtaulds Plc Alginate gels
CA2106804A1 (fr) * 1992-09-24 1994-03-25 James A. Lott Compositions antigel et utilisations de ces compositions
JP3151767B2 (ja) * 1992-11-02 2001-04-03 千寿製薬株式会社 人工唾液
US5496558A (en) * 1993-03-02 1996-03-05 Block Drug Company Inc. Solid form xerostomia product
CN1036700C (zh) * 1993-07-02 1997-12-17 青岛市市立医院 治疗粘膜病损、癌前病变的凝胶状药及其制备方法
NZ260933A (en) * 1993-07-16 1996-07-26 Hercules Inc Cation-complexed polysaccharides; use in foods and pharmaceuticals
US5409691A (en) * 1993-10-18 1995-04-25 Swain; Dan E. Solution comprising aluminum acetate and glycerin
MX9604411A (es) * 1994-03-28 1997-12-31 Univ Columbia Composicion para inactivar irritantes en fluidos.
IL114193A (en) * 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
US5912007A (en) * 1996-02-29 1999-06-15 Warner-Lambert Company Delivery system for the localized administration of medicaments to the upper respiratory tract and methods for preparing and using same
GB9707934D0 (en) 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
WO1999027905A1 (fr) 1997-12-02 1999-06-10 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Compositions pour administration nasale
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
US6358060B2 (en) 1998-09-03 2002-03-19 Jsr Llc Two-stage transmucosal medicine delivery system for symptom relief
US6344222B1 (en) 1998-09-03 2002-02-05 Jsr Llc Medicated chewing gum delivery system for nicotine
PT1117379E (pt) * 1998-10-07 2005-10-31 Giltech Ltd Formulacao espumante e espuma
EP1233751A1 (fr) * 1999-11-29 2002-08-28 ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, Inc. Administration percutan e lente d'une substance biologiquement active
AU2001261744A1 (en) * 2000-05-19 2001-12-03 Npd Llc Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements
US6777000B2 (en) 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
US7494669B2 (en) 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
JP2006348055A (ja) * 2001-03-08 2006-12-28 Rohto Pharmaceut Co Ltd アルギン酸含有組成物
US20020142992A1 (en) * 2001-03-28 2002-10-03 Scherr George H. Cellulosic foam compositions
US6846846B2 (en) * 2001-10-23 2005-01-25 The Trustees Of Columbia University In The City Of New York Gentle-acting skin disinfectants
WO2003066001A2 (fr) * 2002-02-07 2003-08-14 The Trustees Of Columbia University In The City Of New York Compositions de sels de zinc contre l'irritation des muqueuses dues a des spermicides et des microbicides
US7745425B2 (en) * 2002-02-07 2010-06-29 The Trustees Of Columbia University In The City Of New York Non-irritating compositions containing zinc salts
US7879365B2 (en) * 2002-02-07 2011-02-01 The Trustees Of Columbia University In The City Of New York Zinc salt compositions for the prevention of dermal and mucosal irritation
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
US7276246B2 (en) * 2003-05-09 2007-10-02 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7306812B2 (en) * 2003-05-09 2007-12-11 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
EP1651176A4 (fr) * 2003-07-17 2008-05-07 Univ Columbia Compostions antimicrobiennes contenant des combinaisons synergiques de composes d'ammonium quaternaire et d'huiles essentielles et/ou de leurs constituants
US7759327B2 (en) * 2006-01-06 2010-07-20 The Trustees Of Columbia University In The City Of New York Compositions containing zinc salts for coating medical articles
US8642016B2 (en) 2006-07-21 2014-02-04 Jsrnti, Llc Medicinal delivery system, and related methods
DE102008016998A1 (de) * 2008-04-03 2009-10-08 GÖPFERICH, Achim, Prof. Dr. Langsam lösliche quervernetzte Matrices zur Verabreichung von Proteinarzneistoffen
EP3166563B1 (fr) * 2014-07-08 2020-12-16 Fertin Pharma A/S Système d'administration orale comprenant deux compartiments
WO2020045132A1 (fr) * 2018-08-30 2020-03-05 富士フイルム株式会社 Composition de gel externe et procédé d'utilisation de celle-ci
EP3845250B1 (fr) * 2018-08-30 2022-07-06 FUJIFILM Corporation Matériau biocompatible
IT202000007816A1 (it) * 2020-04-14 2021-10-14 Adamas Biotech S R L Presidio medico inibitore di coronavirus

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE670837A (fr) * 1964-10-14 1966-01-31
US3930871A (en) * 1971-03-10 1976-01-06 Kelco Company Thickening compositions
GB1384537A (en) * 1971-05-20 1975-02-19 Sterling Winthrop Group Ltd Wound coverings
US3868260A (en) * 1972-04-13 1975-02-25 Warner Lambert Co Denture adhesive preparation
US3867519A (en) * 1972-04-27 1975-02-18 Alza Corp Bioerodible drug delivery device
CH600878A5 (fr) * 1975-04-28 1978-06-30 Gaba Ag
DE2834320A1 (de) * 1978-08-04 1980-02-28 Tomic Dobrivoje Heilmittel mit entzuendungshemmender und blutstillender wirkung
FR2486392A1 (fr) * 1980-07-10 1982-01-15 Marcy Jean Perfectionnements apportes aux pates destinees a etre appliquees sur les muqueuses et notamment aux pates a usage stomatologique
WO1982000762A1 (fr) * 1980-09-03 1982-03-18 Daigo H Agent pour canal d'alimentation
EP0048123A1 (fr) * 1980-09-12 1982-03-24 Merck & Co. Inc. Emulsion d'algine gélifiée
DE3135567A1 (de) * 1981-09-08 1983-03-17 Laclede Professional Products Inc., New York, N.Y. Abbindende alginat-zusammensetzungen
CA1208558A (fr) * 1982-10-07 1986-07-29 Kazuo Kigasawa Medicament oral
DE3323389A1 (de) * 1983-06-29 1985-01-10 B. Braun Melsungen Ag, 3508 Melsungen Auf schleimhaeute des mundes, der nase und/oder des rachens wirkende arzneimittel auf der basis von heparin und tensiden
JPS60116630A (ja) * 1983-11-29 1985-06-24 Nitto Electric Ind Co Ltd 口腔内製剤
DE3601132A1 (de) * 1986-01-16 1987-07-23 Christian Bannert Verfahren zur behandlung der schleimhaut

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8810121A1 *

Also Published As

Publication number Publication date
JPH02504029A (ja) 1990-11-22
EP0289512A1 (fr) 1988-11-09
WO1988010121A1 (fr) 1988-12-29
WO1987004350A1 (fr) 1987-07-30
EP0289512B1 (fr) 1991-08-14
DE3601132A1 (de) 1987-07-23
DE3721163A1 (de) 1989-01-05
JPS63502186A (ja) 1988-08-25
US5147648A (en) 1992-09-15

Similar Documents

Publication Publication Date Title
EP0365571A1 (fr) Un medicament pour traiter l'oeil et support approprie
EP1455803B2 (fr) Utilisation du panthenol et/ou d'acide pantothénique ou d'acide hyaluronique et/ou de hyaluronate pour la manufacture d'une composition pharmaceutique pour une utilisation ophtalmologique
DE69828993T2 (de) Kontrollierte abgabe von pharmazeutika in der vorderen augenkammer
DE2649095C2 (fr)
DE3856018T2 (de) Verwendung von einer Disaccharidpolysulfat-Aluminium Verbindung zur Herstellung eines Medikaments zur Behandlung von HÄMORRHOIDEN und zur Wundheilung
EP0053754B1 (fr) Médicament pour contre-agir le ronflement et procédé pour son application
EP0619737B1 (fr) Composition pharmaceutique pour le traitement de plaies, cicatrices et cheloides
DE3507024C2 (de) Lösung zur Augenbehandlung
EP1453523B1 (fr) Agent ophtalmique contenant de l'heparine
CH629385A5 (de) Arzneimitteltraeger zum aufbringen einer kompatiblen, pharmakologisch aktiven, chemischen substanz auf eine schleimhaut.
DE69621132T2 (de) Verwendung von hyaluronsäure und eines nsaid zur herstellung eines arzneimittels zur behandlung von krankheiten der mucosa
DE3734835A1 (de) Arzneimittel zur ophthalmologischen anwendung
DE4304893A1 (fr)
EP0773022A2 (fr) Composition pharmaceutique pour le traitement de la rhinite, contenant un sympathomimétique et du pantothenol et/ou l'acide pantothénique
DE2918799A1 (de) Ophthalmische loesung
DE60002719T2 (de) Ophthalmische zusammensetzungen in form wässriger gele
DE60205913T2 (de) Ophthalmische zubereitung mit n-acetylcystein zur behandlung trockener augen
DE3440352A1 (de) Dry-eye-packung
EP0037488A2 (fr) Composition pharmaceutique pour la guérison des affections inflammatoires et/ou dégénératives et/ou atrophiées des membranes muqueuses
US5200180A (en) Pharmaceutical composition for the treatment of the human eye
DE3330053C2 (fr)
DE60132325T2 (de) Ophthalmische lösung
DE69227324T2 (de) Pharmazeutische zusammensetzung, die carbachol und andere cholinerge substanzen enthält
DE3787274T2 (de) Pharmazeutische Präparate, die eine wässerige Lösung eines Pyranoquinolins enthalten.
DE10360425A1 (de) Verwendung von Hyaluronsäure, Hyaluronat und/oder deren Derivate zur Herstellung einer pharmazeutischen Zusammensetzung

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19891222

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19910701

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19930323